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Skin lesions in atopic dermatitis (AD) patients display histo-
logical alterations such as epidermal thickening and inﬁltra-
tion by eosinophils and mast cells (1). The pathogenesis of
AD is believed to involve repeated abnormal innate and
adaptive immune responses to environmental causative agents
when the skin barrier is disrupted (2). Aeroallergens, includ-
ing house dust mites and pollens, are well known to induce
AD through IgE-mediated mechanisms (3). In addition,
microbes represent another important group of extrinsic
causative factors in the pathogenesis of AD (4). Staphylococ-
cus aureus (S. aureus) appears to be particularly important
because it colonizes almost all lesional skin in AD patients,
and a reduction in its colonization has been shown to
decrease disease severity (5–7). Some AD patients produce
IgE antibodies speciﬁc to staphylococcal enterotoxin A or B
(SEA or SEB) (8, 9). Lipoteichoic acid, cell wall component
in S. aureus, has been detected in the lesions of AD patients
and is correlated with AD severity (10). This ﬁnding together
with the fact that about 20–40% of AD patients display
intrinsic AD with no sensitization to any protein allergen
suggests the importance of microbes (11).
Gram-negative bacteria secrete outer membrane vesicles
(OMV) (12), which have pathogenic effects (13, 14). Recently,
we demonstrated for the ﬁrst time that the Gram-positive
bacterium S. aureus produces OMV-like vesicles called extra-
cellular vesicles (EV) (15). The EV produced by S. aureus are
spherical with a diameter of 20–100 nm and are shed from
the bacterium’s membranes. Proteomic analysis revealed that
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Abstract
Background: Recently, we found that Staphylococcus aureus produces extracellular
vesicles (EV) that contain pathogenic proteins. Although S. aureus infection has
been linked with atopic dermatitis (AD), the identities of the causative agents from
S. aureus are controversial. We evaluated whether S. aureus-derived EV are causally
related to the pathogenesis of AD.
Methods: Extracellular vesicles were isolated by the ultracentrifugation of S. aureus
culture media. The EV were applied three times per week to tape-stripped mouse
skin. Inﬂammation and immune dysfunction were evaluated 48 h after the ﬁnal
application in hairless mice. Extracellular vesicles-speciﬁc IgE levels were measured
by ELISA in AD patients and healthy subjects.
Results: The in vitro application of S. aureus EV increased the production of pro-
inﬂammatory mediators (IL-6, thymic stromal lymphopoietin, macrophage inﬂam-
matory protein-1a, and eotaxin) by dermal ﬁbroblasts. The in vivo application of
S. aureus EV after tape stripping caused epidermal thickening with inﬁltration of
the dermis by mast cells and eosinophils in mice. These changes were associated
with the enhanced cutaneous production of IL-4, IL-5, IFN-c, and IL-17. Interest-
ingly, the serum levels of S. aureus EV-speciﬁc IgE were signiﬁcantly increased in
AD patients relative to healthy subjects.
Conclusion: These results indicate that S. aureus EV induce AD-like inﬂammation
in the skin and that S. aureus-derived EV are a novel diagnostic and therapeutic
target for the control of AD.
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in whole bacteria, and that they contain various pathogenic
molecules. Among these, a-hemolysin and cysteine protease
have been linked with AD (16, 17). These ﬁndings suggest
that EV is a potent initiator of host immune responses.
In AD patients, S. aureus, rather than invading and infect-
ing the skin, colonizes it. It is thus reasonable to assume that
the skin is affected by secretory products from S. aureus.
Given that staphylococcal secretory products are relevant to
the pathogenesis of AD, we hypothesized that S. aureus EV,
which are complexes of various pathogenic molecules secreted
by the bacterium, are involved in the pathogenesis of AD. In
this study, we found through in vitro and in vivo studies that
S. aureus EV are causative agents in AD, and the clinical
observation also supports this hypothesis.
Methods
Mice
SKH-HR1 (hairless) mice were purchased from Charles River
Laboratories Japan, Inc. (Yokohama, Japan) and were bred in
a pathogen-free facility at Pohang University of Science and
Technology (POSTECH; Pohang, Korea). All animal experi-
ments were approved by the POSTECH Ethics Committee.
Patients
Skin lavage ﬂuids were obtained from two AD patients visit-
ing Pediatric Clinic of Seoul Suncheonhyang Hospital (Seoul,
Korea). Serum samples were obtained from 60 AD patients
(30 patients aged 6–9 years and 30 patients aged over
10 years) and 20 healthy subjects aged 6–16 years, who were
recruited from Seoul Samsung Hospital (Seoul, Korea). Skin
lavage ﬂuids and serum samples were isolated after written
informed consent had been obtained. The study protocol was
approved by the Ethics Committee of Seoul Suncheonhyang
Hospital and Seoul Samsung Hospital, respectively.
Isolation of Staphylococcus aureus extracellular vesicles
Staphylococcus aureus EV were obtained as described previ-
ously (15). Brieﬂy, S. aureus (ATCC14458) was cultured in
nutrient broth (Merck, Darmstadt, Germany) and grown at
37 C to 1.0 of optical density (at 600 nm). Bacteria were
removed by centrifugation, and the resulting supernatant was
ﬁltered through a 0.45-lm vacuum ﬁlter. The ﬁltrate was
concentrated by ultraﬁltration using the QuixStand Benchtop
System (Amersham Biosciences, Piscataway, NJ, USA) in
conjunction with a 100-kD hollow-ﬁber membrane (Amersham
Biosciences). The resulting concentrated ﬁltrate was passed
through a 0.22-lm vacuum ﬁlter. Extracellular vesicles were
isolated from the resulting ﬁltrate by ultracentrifugation at
150 000 g. The concentration of protein in the EV was mea-
sured by Bradford assays (Bio-Rad Laboratories, Hercules,
CA, USA). Hereafter, the reported doses of EV refer to the
amount of EV protein. Isolated EV were stored at )80 C
before use. Bacteria and EV removed, and then <100 and
>100-kD soluble fractions of bacterial culture media were con-
centrated. Protein concentration was measured by Bradford
assays, and culture media were stored at )80 C before use.
Detection of staphylococcal enterotoxin A and staphylococcal
enterotoxin B
The presence of SEA and SEB in EV and concentrated
culture media was analyzed using SDS-PAGE and western
blot. SEA and SEB were detected by monoclonal anti-SEA
and anti-SEB antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA).
The generation of an atopic dermatitis mouse model using
Staphylococcus aureus extracellular vesicles
To create a mouse model of AD, S. aureus EV were applied
to mouse skin according to the following protocol. To
disrupt the cutaneous barrier, the dorsal skin of 6-week-old
mice was stripped ﬁve to six times using Durapore surgical
tape (3M Co., St. Paul, MN, USA). Gauze (1.5 · 1.5 cm)
soaked with S. aureus EV in 100 ll of phosphate buffered
saline (PBS) was then placed on the stripped skin and secured
using Tegaderm bio-occlusive tape (3M Co.). For the evalua-
tion of inﬂammation and immune dysfunction, the mice were
euthanized 48 h after the ﬁnal challenge.
Histological analysis
Four-micrometer-thick sections of ﬁxed skin tissues were
stained with hematoxylin and eosin (H&E). Mast cells were
stained with toluidine blue (TB). Cells were counted in 15–25
high-power ﬁelds at a magniﬁcation of ·400.
Characterization of T-cell subsets
Single cells of skin-draining lymph nodes (LN) were collected
and stimulated with or without 0.1 lg/ml of S. aureus EV.
Supernatants were harvested after 72 h, and the levels of
cytokines measured by ELISA.
In vitro production of pro-inﬂammatory mediators from
dermal ﬁbroblasts
Primary mouse dermal ﬁbroblasts were isolated as described
previously with some modiﬁcation (18). Fibroblasts from
passages 1–3 were used. Then, 2 · 10
4 cells of isolated
cells were cultured in 24-well plates then treated with 1 or
10 lg/ml S. aureus EV or soluble fractions of bacterial cul-
ture media, or SEB (Toxin Technology, Sarasota, FL, USA).
Supernatants were collected 24 h after stimulation, and medi-
ator levels measured.
Measurement of cytokine and chemokine secretion
The cytokine and chemokine levels were measured by
ELISA (R&D Systems, Mineapolis, MN, USA) according to
the manufacturer’s instructions.
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of patients
Skin lavage ﬂuids were obtained by rinsing patients’ skin
lesions three to four times with 50 ml of sterile PBS and were
stored at )80 C. To remove bacteria and other debris, 40 ml
of skin lavage ﬂuids was centrifuged at 5000 and 10 000 g.
After centrifugation, supernatants were ﬁltered through 0.45
and 0.22 lm serially. Then, lavage ﬂuids were concentrated
to 1 ml by using Centriprep YM-50 (Millipore, Carringtwo-
hill, Ireland). Same volume of PBS was added on concen-
trated lavage ﬂuids, and they were ultracentrifuged at
150 000 g for 3 h at 4 C. The pellet was used as EV fraction.
ELISA assay using anti-Staphylococcus aureus extracellular
vesicles-speciﬁc polyclonal antibodies
Anti-S. aureus EV-speciﬁc polyclonal antibodies were coated
on 96-well ELISA plate. Each well was blocked by 1%
bovine serum albumin in PBS. After blocking, concentrated
lavage ﬂuids and EV fraction were added to each well. Then,
biotinylated anti-S. aureus EV-speciﬁc polyclonal antibodies
were added on each well, and then streptavidin-horseradish
peroxidase (HRP) was added. After a ﬁnal wash, chemilumi-
nescence substrates (POD) were added to react with HRP.
Luminescence measured using a Wallac 1420 Victor lumi-
nometer (American Instrument Exchange, Inc., Haverville,
MA, USA).
Serum antibody ELISA
Mouse
Serum samples were prepared from mouse blood for analysis
of the total serum IgG1 and IgE levels by ELISA (Bethyl
Laboratories, Montgomery, TX, USA) according to manu-
facturer’s instructions.
Human
Staphylococcus aureus EV- and SEB-speciﬁc IgG1 and IgE
levels were measured by ELISA. The wells of 96-well ELISA
plates were each coated with 0.1 lgo fS. aureus EV or 1 lg
of SEB. Then, wells were blocked with 3% bovine serum
albumin in PBS. After blocking, diluted human serum was
added to the wells. Then, HRP-conjugated anti-human
IgG1 and IgE antibodies (Southern Biotech, Birmingham,
IL, USA) were applied to each well. Chemiluminescence
substrates were added, and luminescence was measured by
the luminometer. Speciﬁc antibody levels were deﬁned as ele-
vated if a value is higher than mean +1 standard deviation
of healthy subjects’ values.
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Figure 1 Staphylococcus aureus extracellular vesicles (EV) en-
hance the in vitro secretion of immune and pro-inﬂammatory medi-
ators by mouse dermal ﬁbroblasts. (A) Scanning electron
microscopic images that S. aureus secrete EV. Arrowheads iden-
tify S. aureus EV. (B) Levels of pro-inﬂammatory mediators IL-6,
thymic stromal lymphopoietin, macrophage inﬂammatory protein-
1a and eotaxin in supernatants of dermal ﬁbroblasts after stimula-
tion with EV and >100- and <100-kD soluble fractions of bacterial
culture media. (C) Western blotting to detect staphylococcal
enterotoxin B (SEB) in EV and soluble (Sup) fractions of S. aureus
culture media. (D) Levels of pro-inﬂammatory mediators from
supernatants of dermal ﬁbroblasts after stimulation with EV or
SEB. Assays were performed in duplicate. *P < 0.05; **P < 0.01;
***P < 0.001.
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Statistically signiﬁcant differences between treatments were
identiﬁed using Student’s t-test, anova, or Wilcoxon’s rank
sum test. Multiple comparisons were initially made by anova.
Where signiﬁcant differences were found, individual t-tests or
Wilcoxon’s rank sum tests were used to identify statistically
signiﬁcant differences between treatment group pairs. A
P-value <0.05 was considered to be statistically signiﬁcant.
Results
In vitro production of pro-inﬂammatory mediators from
mouse dermal ﬁbroblasts treated with Staphylococcus aureus
extracellular vesicles
Recently, we found that S. aureus EV contain 90 proteins,
including proteins with pathological function, by proteomic
analysis (15). Scanning electron microscopic images showed
that S. aureus secreted EV (Fig. 1A). We evaluated whether
EV or soluble fractions of S. aureus culture media induce
the production of pro-inﬂammatory mediators from skin
ﬁbroblasts. We found that the production of IL-6, thymic
stromal lymphopoietin (TSLP), macrophage inﬂammatory
protein (MIP)-1a, and eotaxin by dermal ﬁbroblasts was
higher by stimulation with EV than with soluble fraction
(Fig. 1B). It was reported that the presence of IgE antibodies
to SEA and SEB was correlated with the severity of skin
lesions in children with AD (8, 9). Western blotting using anti-
SEA and anti-SEB antibodies showed that SEB was present in
soluble fraction, but not in EV, whereas SEA absent in both
fractions (Fig. 1C). We compared in vitro activity between EV
and SEB on the production of pro-inﬂammatory mediator. As
shown in Fig. 1D, 1 or 10 lg/ml of SEB did not enhance the
production of IL-6, TSLP, MIP-1a, and eotaxin, whereas
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Figure 2 Application of Staphylococcus aureus extracellular vesi-
cles (EV) to tape-stripped mouse skin induces atopic dermatitis-like
inﬂammation. (A) Study protocol: application of different doses of
S. aureus EV to tape-stripped mouse skin for 4 weeks (n = 5 per
treatment group). (B) Skin histology [H&E staining; magniﬁcation,
·200 (upper panel) and ·400 (lower panel)]. Arrowheads identify
eosinophils. (C) Histological analysis of epidermal thickness and
the numbers of eosinophils and mast cells inﬁltrating the dermis.
*P < 0.05; **P < 0.01; ***P < 0.001.
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Collectively, these ﬁndings suggest that S. aureus-derived EV
are more potent compared to soluble components, in terms of
production of pro-inﬂammatory mediators.
Local inﬂammation induced by the application of different
doses of Staphylococcus aureus extracellular vesicles to
tape-stripped mouse skin
We evaluated the in vivo effects of S. aureus EV on the induc-
tion of skin inﬂammation. Different doses of EV were
applied to tape-stripped mouse skin, and changes in skin
inﬂammation were assessed 4 weeks after initial application
(Fig. 2A). Histological analysis showed that the application
of S. aureus EV to tape-stripped skin induced AD-like
inﬂammation, including epidermal thickening and inﬁltration
of the dermis by inﬂammatory cells (Fig. 2B). Moreover, S.
aureus EV dose dependently induced epidermal thickening
(Fig. 2C). As with dermal inﬁltration by inﬂammatory cells,
signiﬁcantly higher numbers of mast cells were found in the
dermis of mice treated with S. aureus EV (at 5 or 10 lg, but
not 0.1 lg) compared to PBS-treated controls. In addition,
the numbers of eosinophils were signiﬁcantly higher in EV-
treated mice than in PBS-treated controls at all doses (Fig. 2
C). Together, these data suggest that the application of S.
aureus EV to tape-stripped skin induces AD-like inﬂamma-
tion.
In vivo immune dysfunction induced by the application of
Staphylococcus aureus extracellular vesicles to tape-stripped
mouse skin for 3 weeks
To test whether the application of S. aureus EV to the skin
induces immunological dysfunction, 5 lgo fS. aureus EV
was applied to tape-stripped mouse skin three times per
week for 3 weeks. Histological analysis showed that the
application of S. aureus EV induced epidermal thickening
and inﬁltration of the dermis by inﬂammatory cells (Fig. 3
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Figure 3 Three-week exposure of tape-stripped mouse skin to
Staphylococcus aureus extracellular vesicles (EV) induces a mixed
Th1-/Th17-/Th2-type inﬂammatory response in the skin, and the
generation of Th1 and Th17 cells in skin-draining lymph nodes
(LNs). Evaluation (n = 5 per treatment group) was performed 48 h
after the ﬁnal application of S. aureus EV (5 lg) (performed three
times a week for 3 weeks) to tape-stripped skin. *P < 0.05;
**P < 0.01; ***P < 0.001. (A) Skin histology [H&E staining; magni-
ﬁcation, ·200]. (B) Histological analysis of epidermal thickness. (C)
Levels of IFN-c and IL-17 in supernatants from S. aureus EV-treated
cells from skin-draining LNs. (D) Levels of IFN-c, IL-17, IL-4, and
IL-5 in skin tissue homogenates.
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B). To characterize the immune dysfunction induced by S.
aureus EV, we measured the production of Th1, Th17, and
Th2 cytokines by T cells from skin-draining LNs following
in vitro stimulation with S. aureus EV. The production of
IFN-c and IL-17 was signiﬁcantly higher in cells from the
EV-treated mice than in those from the PBS-treated animals
(Fig. 3C). IL-4 and IL-5 were not detected in the super-
natants from cells isolated from either treatment group (data
not shown). In terms of the skin production of Th1, Th17,
and Th2 cytokines, the levels of IFN-c, IL-17, IL-4, and
IL-5 in skin homogenates from EV-treated mice were signiﬁ-
cantly higher than those from PBS-treated mice. Tape strip-
ping did not itself enhance the production of these cytokines
(Fig. 3D). With regard to the production of antibodies, we
found the serum levels of total IgG1 and IgE to be similar
in the EV- and PBS-treated mice (data not shown). Collec-
tively, these data suggest that exposure to S. aureus EV for
3 weeks induces a mixed Th1-/Th17-/Th2-type inﬂammatory
response in the skin, whereas a mixed Th1/Th17 cell
response in skin-draining LNs.
Local inﬂammation and systemic immune dysfunction
induced by long-term (8-week) application of Staphylococcus
aureus extracellular vesicles to tape-stripped mouse skin
To assess the effects of long-term exposure to S. aureus EV,
S. aureus EV (5 lg) were applied to tape-stripped skin three
times per week for 8 weeks. Histological analysis showed
that prolonged exposure to S. aureus EV induced epidermal
thickening and increased inﬁltration of the dermis by inﬂam-
matory cells (Fig. 4A,B). Inﬁltration of the dermis by mast
cells and eosinophils was signiﬁcantly increased in EV-treated
mice relative to PBS-treated controls (Fig. 4A,B). Further-
more, long-term in vivo exposure to S. aureus EV enhanced
the production of IL-17 by T cells in skin-draining LNs stim-
ulated with S. aureus EV in vitro (Fig. 4C). However, it did
not enhance the EV-induced production of IFN-c and IL-4
(data not shown). In terms of antibody production following
long-term exposure to S. aureus EV, the serum total IgE lev-
els were signiﬁcantly higher in the EV-treated mice than in
the PBS-treated controls, although the serum total IgG1 lev-
els were similar between the two groups (Fig. 4D). Taken
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Figure 4 Long-term exposure of tape-stripped mouse skin to
Staphylococcus aureus extracellular vesicles (EV) enhances the pro-
duction of IgE. Evaluation (n = 5 per treatment group) was per-
formed 48 h after the ﬁnal application of S. aureus EV (5 lg)
(performed three times a week for 8 weeks) to tape-stripped skin.
*P < 0.05; **P < 0.01; ***P < 0.001. (A) Skin histology [H&E stain-
ing; magniﬁcation, ·200 (upper panel) and ·400 (lower panel)].
Arrowheads identify eosinophils. (B) Histological analysis of
epidermal thickness and numbers of eosinophils and mast cells
inﬁltrating the dermis. (C) Levels of IL-17 in supernatants from S.
aureus EV-treated cells from skin-draining lymph nodes. (D) Serum
levels of total IgG1 and total IgE.
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aureus EV induces IgE production, whereas Th17-cell
response in skin-draining LNs.
The presence of Staphylococcus aureus extracellular vesicles
in the skin lesion of atopic dermatitis patients
We evaluated the presence of S. aureus-derived EV in the
skin lesion of AD patients. To test this objective, EV were
isolated from the skin lesion of two AD patients and then
evaluated whether EV isolated from the skin lesion of AD
patients incorporate S. aureus EV-speciﬁc proteins using anti-
S. aureus EV-speciﬁc polyclonal antibodies. As shown in
Fig. 5, EV isolated from skin lavage ﬂuids of AD patients
contained S. aureus EV-speciﬁc proteins.
Serum Staphylococcus aureus extracellular vesicles-speciﬁc
antibody levels in atopic dermatitis patients
Finally, we measured serum levels of S. aureus EV- and SEB-
speciﬁc antibodies in AD patients and healthy subjects. The
serum levels of S. aureus EV- and SEB-speciﬁc IgG1 were
comparable in AD patients and healthy subjects (Fig. 6A).
By contrast, the serum S. aureus EV-speciﬁc IgE levels were
signiﬁcantly higher in both 6–9 year aged and >9 year aged
AD patients than in age-matched healthy subjects; this IgE
levels were elevated in 33.3% of 6–9 years aged and 40% of
>9 years aged AD patients (Fig. 6B). In addition, the serum
SEB-speciﬁc IgE levels were signiﬁcantly higher in only
>9 years aged AD patients than in age-matched healthy
subjects; this IgE levels were elevated in 33.3% of 6–9 years
aged and 33.3% of >9 years aged AD patients (Fig. 6C).
However, neither total IgE nor SEB-speciﬁc IgE were corre-
lated with S. aureus EV-speciﬁc IgE in AD patients (data not
shown). These ﬁndings indicate that S. aureus EV-speciﬁc
IgE may be a useful biomarker for identifying the cause of
AD in individual cases.
Discussion
Elucidating the pathogenesis of AD has been difﬁcult because
of complex interactions between the causative factors and
host immune response. Among the known causative factors,
microbes are thought to be particularly important in the
pathogenesis of AD by elaborating secretary products,
including soluble toxins. Recently, we found that S. aureus
secretes EV, in which pathogenic proteins are incorporated
(15). In the present study, experimental and clinical data
support the hypothesis that S. aureus EV are involved in the
pathogenesis of AD.
In terms of host immune responses of AD pathogenesis,
recent studies showed that IL-17 producing cells are found in
the blood of AD patients and that AD pathogenesis is
related with IL-17-mediated immune responses (19, 20). In
the present study, we found that the cutaneous application of
S. aureus EV induced Th17-cell response in skin-draining
LNs, suggesting that Th17-cell response is important in the
AD pathogenesis.
The present data showed that the cutaneous application of
S. aureus EV induced skin inﬂammation characterized by
inﬁltration of mast cells and eosinophils. This inﬂammatory
response was associated with enhanced production of not
only Th1/Th17-type cytokines, but also Th2-type cytokines in
the skin. In addition, the present study showed that in vitro
stimulation of ﬁbroblasts with S. aureus EV increased the
secretion of the Th2-type cytokines, such as TSLP and
eotaxin (21). These ﬁndings suggest that Th2-type inﬂamma-
tion induced by S. aureus EV is mediated by local production
of Th2-type cytokines from dermal ﬁbroblasts.
Staphylococcus aureus can colonize in skin or nasal pas-
sage in human (22). In the present study, we ﬁrstly demon-
strated that S. aureus-derived EV are present on the skin of
AD patients. We also found that S. aureus EV-speciﬁc IgG1
were detected in serums from not only AD patients but
also healthy subjects. These ﬁndings suggest that S. aureus
secretes EV in skin, which induce systemic immune
responses.
Previous studies showed that serum levels of IgE speciﬁc
to staphylococcal enterotoxins were not only elevated in
AD patients, but also correlated with disease severity (8, 9).
Our present data indicate that serum levels of both S. aur-
eus EV- and SEB-speciﬁc IgE were elevated in the AD
patients compared to healthy subjects. In addition, the pres-
ent study showed that S. aureus EV did not contain entero-
toxins and S. aureus EV-speciﬁc IgE levels did not correlate
with SEB-speciﬁc IgE. These ﬁndings suggest that the
production of EV-speciﬁc IgE is not inﬂuenced by staphylo-
coccal enterotoxins.
Recently, it was reported that IL-17 can induce IgE
production in B cells (23). The present study showed that the
cutaneous application of S. aureus EV for 8 weeks induce
Th17-cell response, but not Th2-cell response, along with the
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Figure 5 Staphylococcus aureus-derived extracellular vesicles
(EV) are present on the skin of atopic dermatitis (AD) patients. This
ﬁgure showed ELISA assay to detect S. aureus EV-speciﬁc proteins
using anti-S. aureus EV polyclonal antibodies; lavage ﬂuids and
EV fraction of lavage ﬂuids obtained from two AD patients have
S. aureus EV-speciﬁc proteins (SA_EV, S. aureus-derived EV).
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Allergy 66 (2011) 351–359 ª 2010 John Wiley & Sons A/S 357elevation of serum total IgE in mice. These ﬁndings suggest
that S. aureus EV can induce systemic IgE production by
Th17-cell response.
Recent evidence indicates that EV from Gram-negative
bacteria induced systemic inﬂammatory response (13). We
found that Gram-positive bacteria produced EV (15). This
is the ﬁrst report to show that EV obtained from
Gram-positive bacteria can cause inﬂammatory disease.
Given the abundance of Gram-positive bacteria in our
environment, further research will be needed to elucidate
the relationships between EV from Gram-positive bacteria
and the pathogenesis of immune-based inﬂammatory dis-
eases.
In summary, our present data indicate that S. aureus-
derived EV can induce AD-like inﬂammation in the skin,
and that the physiological animal model we employed repre-
sents a useful tool for performing translational research into
AD. Furthermore, our clinical ﬁndings provide strong evi-
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Figure 6 Staphylococcus aureus extracellular vesicles (EV)-speciﬁc
IgE is elevated in atopic dermatitis (AD) patients than in age-
matched healthy subjects. (A) Levels of S. aureus EV-speciﬁc (left
panel) and SEB-speciﬁc (right panel) IgG1 in serum from AD
patients and healthy subjects. (B) Levels of S. aureus EV-speciﬁc
IgE in serum from AD patients and healthy subjects (left panel),
and positive rate of elevated S. aureus EV-speciﬁc IgE in AD
patients (right panel). (C) Levels of SEB-speciﬁc IgE in serum from
AD patients and healthy subjects (left panel), and positive rate of
elevated SEB-speciﬁc IgE in AD patients (right panel). Serum
samples from AD patients (n = 30 in patients aged 6–9 years, and
n = 30 in patients aged 9–16 years) and healthy subjects aged
6–16 years (n = 20); EV, S. aureus-derived EV; SEB, staphylococcal
enterotoxin B. *P < 0.05; **P < 0.01.
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of AD.
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